Future of cord blood for oncology uses

C. G. Brunstein; D. J. Weisdorf

doi:10.1038/bmt.2009.286

Future of cord blood for oncology uses

C. G. Brunstein, D. J. Weisdorf

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

The utilization of umbilical cord blood (UCB) as a source of stem cells for transplantation has grown substantially in the last decade. Already an established practice for the treatment of children with hematological malignancies, its application for the treatment of adults is also expanding. The development of the double UCB and reduced-intensity transplantation platforms have contributed to this expansion. Recent registry-based analysis and ongoing single institution and multicenter clinical trials are investigating ways to make UCB transplantation more widely available. We review here the background data on the utilization of UCB for the treatment of hematological malignancies, and discuss the current challenges and future directions in the field of UCB transplantation.

Original language	English (US)
Pages (from-to)	699-707
Number of pages	9
Journal	Bone marrow transplantation
Volume	44
Issue number	10
DOIs	https://doi.org/10.1038/bmt.2009.286
State	Published - Nov 2009

Keywords

Double umbilical cord blood transplantation
Hematological malignancies
Reducedintensity conditioning
Umbilical cord blood transplantation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1038/bmt.2009.286

OpenUrl availability

Full text

Cite this

@article{2b45cd916e66419ea5a453703d3ca20b,

title = "Future of cord blood for oncology uses",

abstract = "The utilization of umbilical cord blood (UCB) as a source of stem cells for transplantation has grown substantially in the last decade. Already an established practice for the treatment of children with hematological malignancies, its application for the treatment of adults is also expanding. The development of the double UCB and reduced-intensity transplantation platforms have contributed to this expansion. Recent registry-based analysis and ongoing single institution and multicenter clinical trials are investigating ways to make UCB transplantation more widely available. We review here the background data on the utilization of UCB for the treatment of hematological malignancies, and discuss the current challenges and future directions in the field of UCB transplantation.",

keywords = "Double umbilical cord blood transplantation, Hematological malignancies, Reducedintensity conditioning, Umbilical cord blood transplantation",

author = "Brunstein, {C. G.} and Weisdorf, {D. J.}",

year = "2009",

month = nov,

doi = "10.1038/bmt.2009.286",

language = "English (US)",

volume = "44",

pages = "699--707",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Future of cord blood for oncology uses

AU - Brunstein, C. G.

AU - Weisdorf, D. J.

PY - 2009/11

Y1 - 2009/11

N2 - The utilization of umbilical cord blood (UCB) as a source of stem cells for transplantation has grown substantially in the last decade. Already an established practice for the treatment of children with hematological malignancies, its application for the treatment of adults is also expanding. The development of the double UCB and reduced-intensity transplantation platforms have contributed to this expansion. Recent registry-based analysis and ongoing single institution and multicenter clinical trials are investigating ways to make UCB transplantation more widely available. We review here the background data on the utilization of UCB for the treatment of hematological malignancies, and discuss the current challenges and future directions in the field of UCB transplantation.

AB - The utilization of umbilical cord blood (UCB) as a source of stem cells for transplantation has grown substantially in the last decade. Already an established practice for the treatment of children with hematological malignancies, its application for the treatment of adults is also expanding. The development of the double UCB and reduced-intensity transplantation platforms have contributed to this expansion. Recent registry-based analysis and ongoing single institution and multicenter clinical trials are investigating ways to make UCB transplantation more widely available. We review here the background data on the utilization of UCB for the treatment of hematological malignancies, and discuss the current challenges and future directions in the field of UCB transplantation.

KW - Double umbilical cord blood transplantation

KW - Hematological malignancies

KW - Reducedintensity conditioning

KW - Umbilical cord blood transplantation

UR - http://www.scopus.com/inward/record.url?scp=75149187813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149187813&partnerID=8YFLogxK

U2 - 10.1038/bmt.2009.286

DO - 10.1038/bmt.2009.286

M3 - Review article

C2 - 19802022

AN - SCOPUS:75149187813

SN - 0268-3369

VL - 44

SP - 699

EP - 707

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 10

ER -

Future of cord blood for oncology uses

Abstract

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this